Paper published Added
PubMed
Genetic Tests Can't Tell You Which ADHD Medication Will Work Best for Your Child
A review of genetic testing for children's mental health medication says these tests may help flag side-effect risk in some children. They can't predict which medication will work best for a particular child. The authors also warn that some commercial reports use simple color-coding that can mislead both families and doctors.
What you can do
If you're considering a genetic test for a child's ADHD medication, treat it as a possible tool for anticipating side-effect risk, not for choosing the most effective drug, and go over any color-coded report with a clinician who understands its limits.
Evidence
- Study design
- narrative review
- Population
- Children and adolescents with depression, anxiety, or ADHD (pediatric populations; no specific sample described)
- Sample size
- Abstract-only; no sample size reported. Appears to be a narrative/expository review, so this is not a primary-data study.
- Intervention / exposure
- Pharmacogenomic testing to inform psychotropic medication selection (no dose or duration specified)
- Comparator
- Not reported
- Key results
- Utility of pharmacogenomic testing for identifying psychotropic medication tolerability or adverse effects: Authors state testing 'can be useful in certain populations to identify a psychotropic medication's tolerability or adverse effects.' No quantitative data in abstract.
- Ability of pharmacogenomic testing to predict clinical response: Authors state testing 'cannot predict which medication will provide the best clinical response in a specific patient with a specific mental illness.'
- Limitations
- Abstract-only extraction; no methods, search strategy, or data are available, so the design is inferred as narrative review from the content.
- Authors note testing 'require[s] nuanced understanding and interpretation' in pediatric depression, anxiety, and ADHD.
- Authors state testing cannot predict which medication will give the best clinical response.
- Authors caution that some commercial kits give clinical guidance based on genetic tests that 'may not have clinical relevance' in an 'over-simplified color-coded format which can be misleading for the patient and for the clinician.'
- Usefulness is described as limited to 'certain populations' for tolerability/adverse effects; the populations are not specified in the abstract.
- Source reviewed
- Abstract
References
Rahmani M. Utility of pharmacogenomic tests in treating pediatric depression, anxiety and ADHD. Current problems in pediatric and adolescent health care. 2026-10-16